FrancoAntonio BFelizartaMD

Infectious Disease • Bakersfield, CA

HIV/AIDS Medicine

solo private practice

Join to view full profile

Dr. Felizarta is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Felizarta's full profile

Already have an account?

Office
3535 San Dimas Street
Suite 24
Bakersfield, CA 93311
Phone+1 661-324-3128

Fax+1 661-324-1129

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Infectious Disease, 1995 - 1997
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1992 - 1995
University of the Philippines College of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1997 - 2025
NJ State Medical License 1996 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy Start of enrollment: 2002 Mar 01
Completed
Phase 4
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Start of enrollment: 2004 Jun 01
Completed
Phase 4
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults Start of enrollment: 2005 Aug 01
Terminated
Phase 2
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects Start of enrollment: 2005 Nov 02
Completed
Phase 2
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Start of enrollment: 2006 Mar 01
Completed
Phase 4
Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea Start of enrollment: 2007 Oct 01
Completed
Phase 3
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study) Start of enrollment: 2007 Mar 01
Completed
Prospective Observational Epidemiologic Study of Maraviroc's Safety Start of enrollment: 2008 Mar 31
Completed
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults Start of enrollment: 2008 Jun 01
Completed
Phase 2
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Start of enrollment: 2009 Jul 30
Completed
Phase 2
Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C Start of enrollment: 2009 Aug 01
Withdrawn
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects Start of enrollment: 2009 Sep 01
Completed
Phase 4
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine Start of enrollment: 2010 Mar 22
Completed
Phase 1
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Start of enrollment: 2010 Apr 01
Completed
Phase 4
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Start of enrollment: 2010 Oct 05
Terminated
Phase 2
Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons Start of enrollment: 2010 Nov 08
Completed
Phase 2
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults Start of enrollment: 2010 Oct 26
Completed
Phase 3
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Start of enrollment: 2011 Feb 01
Completed
Phase 3
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy Start of enrollment: 2011 Feb 01
Completed
Phase 3
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients Start of enrollment: 2011 Feb 01
Completed
Phase 3
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study Start of enrollment: 2011 Dec 01
Completed
Phase 3
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Start of enrollment: 2011 May 18
Completed
Phase 4
3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection Start of enrollment: 2011 Jul 04
Completed
Phase 3
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea Start of enrollment: 2011 Jun 07
Completed
Phase 3
Gilead Sustained Virologic Response (SVR) Registry Start of enrollment: 2012 Apr 13
Completed
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response Start of enrollment: 2011 Dec 19
Completed
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients Start of enrollment: 2011 Oct 01
Completed
Phase 2
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients Start of enrollment: 2012 Jan 01
Completed
Phase 2
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) Start of enrollment: 2011 Dec 01
Terminated
Phase 3
Phase 3 Study of Sofosbuvir and Ribavirin Start of enrollment: 2011 Dec 01
Completed
Phase 3
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects Start of enrollment: 2012 Feb 01
Completed
Phase 2
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir Start of enrollment: 2012 Apr 18
Completed
Phase 3
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies Start of enrollment: 2012 Jun 01
Completed
Phase 3
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine Start of enrollment: 2012 Aug 06
Completed
Phase 2
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection Start of enrollment: 2012 Aug 01
Completed
Phase 2
A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study Start of enrollment: 2013 Jun 01
Completed
Phase 3
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants Start of enrollment: 2013 Apr 01
Completed
Phase 2
Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis Start of enrollment: 2013 Jun 01
Completed
Phase 2
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Start of enrollment: 2013 Aug 22
Completed
Phase 3
An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine Start of enrollment: 2013 Apr 01
Completed
Phase 2
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
Completed
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option Start of enrollment: 2014 Mar 01
Completed
Phase 2
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir Start of enrollment: 2014 Feb 01
Completed
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis Start of enrollment: 2014 Apr 01
Completed
Phase 3
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis Start of enrollment: 2014 Apr 01
Completed
Phase 3
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 Jun 12
Completed
Phase 3
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease Start of enrollment: 2014 Aug 21
Terminated
Phase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection Start of enrollment: 2014 Aug 01
Completed
Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection Start of enrollment: 2014 Sep 19
Completed
Phase 2, Phase 3
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) Start of enrollment: 2014 Dec 01
Completed
Phase 3
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection Start of enrollment: 2015 Jan 01
Completed
Phase 2
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) Start of enrollment: 2015 Jun 05
Completed
Phase 3
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 Start of enrollment: 2015 Jun 22
Completed
Phase 2, Phase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy Start of enrollment: 2015 Apr 01
Completed
Phase 2, Phase 3
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Apr 05
Terminated
Phase 3
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis Start of enrollment: 2017 Feb 14
Terminated
Phase 2
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Start of enrollment: 2017 Apr 28
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care Start of enrollment: 2017 Jul 31
Completed
Phase 3
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Start of enrollment: 2017 Aug 22
Completed
Phase 2
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection Start of enrollment: 2018 Feb 13
Completed
Phase 2
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. Start of enrollment: 2019 Jan 04
Completed
Phase 2
ACTIV-2: A Study for Outpatients With COVID-19 Start of enrollment: 2020 Aug 19
Completed
Phase 2, Phase 3
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation Start of enrollment: 2020 Sep 14
Completed
Phase 1, Phase 2
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 Start of enrollment: 2023 Oct 12
Recruiting
Phase 2
Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1) Start of enrollment: 2021 Apr 16
Completed
Phase 1
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection Start of enrollment: 2019 Aug 01
Completed
Phase 2
Advancing Dignity, Health, and Optimism in Connection With Long Acting Injectables Start of enrollment: 2021 May 20
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 Start of enrollment: 2020 Jan 30
Completed
Phase 1
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
Join now to see all

Publications & Presentations

PubMed

1 citations
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson
Infectious Diseases and Therapy. 2024-04-01
11 citations
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic h...
Man-Fung Yuen, Tarik Asselah, Ira M Jacobson, Maurizia Rossana Brunetto, Harry L A Janssen
The Lancet. Gastroenterology & Hepatology. 2023-09-01
3 citations
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the...
Tahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, Ahmed Hnoosh, Antonella Castagna
AIDS Patient Care and Stds. 2023-01-01

Press Mentions

Fast Vaccine Rollout Sought to Fight DeltaJuly 21st, 2021

Professional Memberships

American College of Physicians - ACP
Fellow
American Medical Association - AMA
Member
Infectious Disease Society of America - IDSA
Member
California Medical Association - CMA
Member

Other Languages

Tagalog